FDA.reportPublic FDA data

brimonidine 0.0033 MG/MG Topical Gel [Mirvaso]

RxCUI
1437709
RxNorm name
brimonidine 0.0033 MG/MG Topical Gel [Mirvaso]
Display name
brimonidine 0.0033 MG/MG Topical Gel [Mirvaso]
Full name
brimonidine 0.0033 MG/MG Topical Gel [Mirvaso]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:28

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
f6a4353f-ae69-4214-901f-e5d42a6fbde7Mirvaso 0.33 % Topical Gel [PSN] · brimonidine 0.0033 MG/MG Topical Gel [Mirvaso] [SBD] · Mirvaso 0.0033 MG/MG Topical Gel [SY] · Mirvaso 0.33 % (as brimonidine tartrate 5 mg/ml) Topical Gel [SY]411These highlights do not include all the information needed to use MIRVASO ® safely and effectively. See full prescribing information for MIRVASO. MIRVASO (brimonidine) topical gel Initial U.S. Approval: 199620241024